TELA Bio, Inc.
NASDAQ:TELAMedical - Devices
+$0.09 today
- Market cap
- $51.00M
- Beta
- 1.36
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.72
Volume 0.22M
Average 0.17M
TELA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
TELA Bio, Inc.NASDAQ: TELA
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $11.26M (cash outflow) rose 13.5% year over year, ahead of the +1.0% change in trailing-twelve-month net income. Sequentially, it fell 8.2% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.
Context
- Net income amounted to 48.4% of revenue in FY2025, down 6.2 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$31.82M (-18.1%) for the fiscal year ending Dec 2026, a slowdown from the +2.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$11.26M-8.2% QoQ
- Last fiscal yearDec 2025
- -$38.83M+2.6% YoY
- LTMJun 2026
- -$41.18M+1.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.5% | +3.9% | -9.6 pp |
| 1 year | +2.6% | -18.1% | -20.7 pp |
| 3-year CAGR | -4.3% | -26.0% | -21.7 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (38.83M) USD
- Year-over-year change
- -2.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.83M) | -2.6% |
| FY2024 | 2024-12-31 | (37.84M) | +18.9% |
| FY2023 | 2023-12-31 | (46.66M) | -5.3% |
| FY2022 | 2022-12-31 | (44.3M) | -33.1% |
| FY2021 | 2021-12-31 | (33.28M) | — |
Net Income vs competitors
How TELA compares with its peers on the latest reported figures
- TELA's LTM Jun 2026 net income of $41.18M is the 2nd largest of the 9 companies compared; the peer median is $19.29M.
- Its year-over-year change of +1.0% is the 5th highest of 9, against a peer median of -15.6%.
- Net income amounts to 51.5% of revenue for TELA, versus a peer median of 491.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Jun 2026 | $41.18M | +1.0% | -4.3% | 51.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
MDAISpectral AI, Inc. | LTM Mar 2026 | $13.88M | +50.7% | +37.5% | 83.1% |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| LTM Mar 2026 | $7.77M | -531.6% | — | 34.5% | |
| Peer median (excluding TELA) | $19.29M | -15.6% | -10.4% | 491.3% | |
Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.28M) | (44.3M) | (46.66M) | (37.84M) | (38.83M) |
| Depreciation & Amortization | 535K | 1.19M | 808K | 1.01M | 1.01M |
| Deferred Income Tax | 14K | 0 | 0 | (144K) | 230K |
| Stock-Based Compensation | 3.66M | 3.99M | 5.03M | 4.36M | 3.8M |
| Change in Working Capital | (3.47M) | (5.76M) | (1.67M) | (4.87M) | 1.5M |
| Accounts Receivables | (1.55M) | (2.42M) | (3.06M) | (762K) | (110K) |
| Inventory | (5.19M) | (6.07M) | (2.72M) | (2.97M) | (503K) |
| Accounts Payables | 1.6M | (884K) | 11K | 482K | 141K |
| Other Working Capital | 1.69M | 3.62M | 4.1M | (1.62M) | 1.97M |
| Other Non-Cash Items | 2.1M | 4.14M | 1.64M | (4.12M) | 4.08M |
| Operating Cash Flow | (30.43M) | (40.75M) | (40.86M) | (41.6M) | (28.22M) |
| Capital Expenditures | (627K) | (1.87M) | (611K) | (989K) | (448K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1.29M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (1M) | 12K | 5.44M | 0 |
| Investing Cash Flow | (627K) | (1.87M) | (599K) | 4.45M | 846K |
| Debt Repayment | 0 | 10M | 0 | 0 | 14.03M |
| Common Stock Issued | 585K | 34.4M | 46.34M | 42.92M | 11.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 105K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.55M) | (74K) | 138K | (205K) |
| Financing Cash Flow | 585K | 40.85M | 46.27M | 43.06M | 25.75M |
| Effect of Forex Changes | 11K | (144K) | 164K | 28K | (217K) |
| Net Change in Cash | (30.46M) | (1.91M) | 4.98M | 5.94M | (1.84M) |
| Free Cash Flow | (31.06M) | (42.62M) | (41.47M) | (42.58M) | (28.67M) |
TELA Bio, Inc.
NASDAQ:TELA
Intrinsic Alpha fair value
Locked
Current Price
$1.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.